LEADER 01852nam  2200373   450 
001 9910688593703321
005 20230628090930.0
035   $a(CKB)5400000000043272
035   $a(NjHacI)995400000000043272
035   $a(EXLCZ)995400000000043272
100   $a20230628d2021      uy             0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aLung Cancer /$fedited by Henry S. Park
210  1$aLondon, England :$cIntechOpen,$d2021.
215   $a1 online resource (224 pages)
311   $a1-78985-638-8 
330   $aLung cancer continues to be the leading cause of cancer mortality worldwide among both men and women. Recent advances in prevention, screening and management in the past decade have led to significant improvements in survival and quality of life. Local treatments like minimally invasive surgery, radiotherapy, and image-guided ablation have contributed to improving the effectiveness and tolerability of potentially curative treatments in early-stage, locally advanced, and oligometastatic/oligoprogressive disease. Chemotherapy, targeted therapy, immunotherapy, and palliative local therapy options have expanded rapidly, with new regimens showing improved outcomes even for those with widely metastatic disease. This book comprehensively reviews the evidence that has driven personalized medicine, based on a variety of multidisciplinary perspectives by international lung cancer experts.
517   $aLung Cancer 
606   $aLungs$xCancer
606   $aOncology
615  0$aLungs$xCancer.
615  0$aOncology.
676   $a616.99424
702   $aPark$b Henry S.
801  0$bNjHacI
801  1$bNjHacl
906   $aBOOK
912   $a9910688593703321
996   $aLung cancer$91890569
997   $aUNINA